194 related articles for article (PubMed ID: 36032124)
1. Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
Li C; Zheng X; Li P; Wang H; Hu J; Wu L; Wang Z; Guo H; Wu F; Zhong W; Zhou C; Chu Q; Zhao J; Zheng X; Xiao W; Zhu W; Zhang L; Li Q; Jiang K; Miao Q; Wu B; Xu Y; Wu S; Wang H; Yang S; Li Y; Xia X; Yi X; Huang C; Zhu B; Lin G
Front Immunol; 2022; 13():944812. PubMed ID: 36032124
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
3. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
4. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
6. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
9. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
12. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
13. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
14. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
[TBL] [Abstract][Full Text] [Related]
15. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
18. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series.
Ward JD; Fowler M; Robledo-Gomez A; Goodyear SM; Kardosh A; Sasatomi E
J Gastrointest Oncol; 2024 Apr; 15(2):768-779. PubMed ID: 38756636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]